Conditions: Hypertension Unspecified Adult Solid Tumor, Protocol Specific
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure.

PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.

Detailed description:
PRIMARY OBJECTIVES:

I. To determine which drug has the greatest effect on Ang-(1-7) levels in cancer patients with hypertension.

SECONDARY OBJECTIVES:

I. To determine the effect of these drugs on levels of Ang II, VEGF, PlGF, and ACE in the same patients.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

* ARM I: Patients receive oral benazepril hydrochloride once daily on days 1-7.
* ARM II: Patients receive oral lisinopril once daily on days 1-7.
* ARM III: Patients receive oral ramipril twice daily on days 1-7.
* ARM IV: Patients receive oral losartan potassium once daily on days 1-7. In all arms, treatment continues in the absence of unacceptable toxicity.

Arms:
arm 1: Patients receive oral benazepril hydrochloride once daily on days 1-7. arm 2: Patients receive oral lisinopril once daily on days 1-7. arm 3: Patients receive oral ramipril twice daily on days 1-7. arm 4: Patients receive oral losartan potassium once daily on days 1-7.

Interventions: intervention 1: lisinopril intervention 2: losartan potassium intervention 3: laboratory biomarker analysis intervention 4: benazepril hydrochloride intervention 5: ramipril
Intervention descriptions: intervention 1: Given orally intervention 2: Given orally intervention 3: Correlative studies intervention 4: Given orally intervention 5: Given orally

Protocol document: